AAREYDRUGS.NSAAREYDRUGS.NSNSE
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +74.94% | -48.61% | -19.47% | -19.96% | -27.93% |
| Gross Profit Growth | +8.40% | -97.90% | +31.82% | -55.12% | -139.45% |
| EBITDA Growth | -3.88% | -27.43% | +18.18% | -8.25% | -152.54% |
| Operating Income Growth | -27.37% | +0.00% | -52.89% | -39.70% | -244.34% |
| Net Income Growth | -62.37% | -78.15% | +10.67% | -35.87% | -20.68% |
| EPS Growth | -65.33% | -77.92% | +9.09% | -36.84% | -23.08% |
| EPS Diluted Growth | -65.33% | -77.92% | +9.09% | -36.84% | -23.08% |
| Weighted Average Shares Growth | +10.52% | +10.52% | +1.43% | +1.37% | +1.43% |
| Weighted Average Shares Diluted Growth | +10.52% | +10.52% | +1.43% | +1.37% | +1.43% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | -100.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | -100.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +0.00% | -20.56% | +0.00% | +420.06% | +0.00% |
| Inventory Growth | +0.00% | -36.83% | +0.00% | +31.13% | +0.00% |
| Asset Growth | +0.00% | -21.88% | +0.00% | +7.09% | +0.00% |
| Book Value per Share Growth | +3.17% | -5.63% | +2.83% | +8.29% | +0.00% |
| Debt Growth | +0.00% | +11.18% | +0.00% | +31.38% | +0.00% |
| R&D Expense Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| SG&A Expenses Growth | -5.22% | +0.00% | -5.15% | -64.15% | +9.94% |